Public disclosures

Beltran Pedro

Company insiders · President and CEO · Director · BridgeBio Oncology Therapeutics, Inc.

Advertisement
FollowLatest SEC filingSEC filer historyProfile details as reported on 2026-11-20.Following & alerts
Reported transaction lines
1
Buy lines
0
Sell lines
1

Filing activity by month

Original filing lines in up to 12 months with activity.

  • 2026-111

Frequently disclosed stocks

Disclosure history

More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSource
Beltran Pedro

President and CEO · Director · BridgeBio Oncology Therapeutics, Inc.

BBOT

BridgeBio Oncology Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 41659 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 19, 2026. · The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.80 to $1.94. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

2026-11-182026-11-20

≈ $3,442.67

1,870 shares/units

SEC 4

Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.

Advertisement